tiprankstipranks
Charles River Laboratories Intl (MX:CRL)
NYSE:CRL
Mexico Market
CRL
Charles River Labs
RESEARCH TOOLSreports

Charles River Labs (CRL) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

CRL Analyst Ratings

Strong Buy
12Ratings
Strong Buy
10 Buy
2 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Charles
River Labs
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRL Stock 12 Month Forecast

Average Price Target

$4,024.90
▲(1.64% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Charles River Labs in the last 3 months. The average price target is $4,024.90 with a high forecast of $4,633.35 and a low forecast of $3,724.17. The average price target represents a 1.64% change from the last price of $3,960.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3157":"$3,157","4634":"$4,634","3526.25":"$3,526.3","3895.5":"$3,895.5","4264.75":"$4,264.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4633.35315015,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.63K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4024.8977176020003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.02K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3724.16687163,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.72K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3157,3526.25,3895.5,4264.75,4634],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3269.1,3374.0425500115384,3478.985100023077,3583.9276500346155,3688.870200046154,3793.8127500576925,3898.7553000692305,4003.697850080769,4108.640400092308,4213.582950103846,4318.525500115385,4423.468050126923,4528.410600138462,{"y":4633.35315015,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3269.1,3327.2382859693844,3385.3765719387693,3443.5148579081538,3501.6531438775387,3559.791429846923,3617.9297158163076,3676.0680017856926,3734.206287755077,3792.344573724462,3850.4828596938464,3908.621145663231,3966.759431632616,{"y":4024.8977176020003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3269.1,3304.1051439715384,3339.110287943077,3374.1154319146153,3409.120575886154,3444.1257198576923,3479.1308638292307,3514.136007800769,3549.1411517723077,3584.146295743846,3619.1514397153846,3654.156583686923,3689.1617276584616,{"y":3724.16687163,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4066.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4066.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4066.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3158.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3158.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3158.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3282.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3282.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3282.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3282.96,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3282.96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 54, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3282.96,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 70, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3269.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 65, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$4,633Average Price Target$4,025Lowest Price Target$3,724
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CLSA Analyst forecast on MX:CRL
Michael Luo CFA
CLSA
CLSA
$3,829.07
Hold
-3.31%
Downside
Downgraded
07/20/26
Charles River downgraded to Hold from Outperform at CLSACharles River downgraded to Hold from Outperform at CLSA
Mizuho Securities Analyst forecast on MX:CRL
Ann Hynes
Mizuho Securities
Mizuho Securities
$3,357→$4,021.4
Hold
1.55%
Upside
Reiterated
07/13/26
Charles River price target raised to $230 from $192 at MizuhoCharles River price target raised to $230 from $192 at Mizuho
Morgan Stanley Analyst forecast on MX:CRL
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$3,846.56→$4,545.93
Buy
14.80%
Upside
Assigned
07/09/26
Charles River price target raised to $260 from $220 at Morgan StanleyCharles River price target raised to $260 from $220 at Morgan Stanley
Citi Analyst forecast on MX:CRL
Patrick B Donnelly
Citi
Citi
$4,633.35
Buy
17.00%
Upside
Reiterated
07/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on MX:CRL
Ryan Halsted
RBC Capital
RBC Capital
$3,759.14
Buy
-5.07%
Downside
Reiterated
07/08/26
RBC Capital Keeps Their Buy Rating on Charles River Labs (CRL)
Barclays Analyst forecast on MX:CRL
Luke Sergott
Barclays
Barclays
$3,846.56
Buy
-2.86%
Downside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL), Incyte (NASDAQ: INCY) and Pfizer (NYSE: PFE)
Bank of America Securities Analyst forecast on MX:CRL
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
06/05/26
Analysts Are Bullish on Top Healthcare Stocks: Charles River Labs (CRL), TransMedics Group (TMDX)
TD Cowen Analyst forecast on MX:CRL
Charles Rhyee
TD Cowen
TD Cowen
$4,108.82
Buy
3.76%
Upside
Reiterated
06/04/26
We reiterate our Buy rating
William Blair Analyst forecast on MX:CRL
Max Smock
William Blair
William Blair
―
Buy
―
Reiterated
06/02/26
Max Smock Reiterates Buy on Charles River Laboratories, Citing Achievable 2026 Targets and Margin Expansion Upside
Jefferies Analyst forecast on MX:CRL
David Windley
Jefferies
Jefferies
$3,933.98
Buy
-0.66%
Downside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (NASDAQ: PSTV) and Charles River Labs (NYSE: CRL)
Robert W. Baird Analyst forecast on MX:CRL
Eric Coldwell
Robert W. Baird
Robert W. Baird
$3,496.87→$3,724.17
Buy
-5.96%
Downside
Reiterated
05/08/26
Charles River price target raised to $213 from $200 at BairdCharles River price target raised to $213 from $200 at Baird
Evercore ISI Analyst forecast on MX:CRL
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$3,496.87→$3,846.56
Buy
-2.86%
Downside
Reiterated
05/08/26
Charles River price target raised to $220 from $200 at Evercore ISICharles River price target raised to $220 from $200 at Evercore ISI
J.P. Morgan Analyst forecast on MX:CRL
Casey Woodring
J.P. Morgan
J.P. Morgan
$2,884.92→$2,797.5
Hold
-29.36%
Downside
Assigned
04/13/26
Charles River price target lowered to $160 from $165 at JPMorganCharles River price target lowered to $160 from $165 at JPMorgan
Argus Research Analyst forecast on MX:CRL
David Toung
Argus Research
Argus Research
$3,496.87
Buy
-11.70%
Downside
Upgraded
11/17/25
Charles River upgraded to Buy from Hold at ArgusCharles River upgraded to Buy from Hold at Argus
Deutsche Bank Analyst forecast on MX:CRL
Justin Bowers
Deutsche Bank
Deutsche Bank
$3,147.18→$3,234.61
Buy
-18.32%
Downside
Reiterated
08/07/25
Deutsche Bank Keeps Their Buy Rating on Charles River Labs (CRL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CLSA Analyst forecast on MX:CRL
Michael Luo CFA
CLSA
CLSA
$3,829.07
Hold
-3.31%
Downside
Downgraded
07/20/26
Charles River downgraded to Hold from Outperform at CLSACharles River downgraded to Hold from Outperform at CLSA
Mizuho Securities Analyst forecast on MX:CRL
Ann Hynes
Mizuho Securities
Mizuho Securities
$3,357→$4,021.4
Hold
1.55%
Upside
Reiterated
07/13/26
Charles River price target raised to $230 from $192 at MizuhoCharles River price target raised to $230 from $192 at Mizuho
Morgan Stanley Analyst forecast on MX:CRL
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$3,846.56→$4,545.93
Buy
14.80%
Upside
Assigned
07/09/26
Charles River price target raised to $260 from $220 at Morgan StanleyCharles River price target raised to $260 from $220 at Morgan Stanley
Citi Analyst forecast on MX:CRL
Patrick B Donnelly
Citi
Citi
$4,633.35
Buy
17.00%
Upside
Reiterated
07/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on MX:CRL
Ryan Halsted
RBC Capital
RBC Capital
$3,759.14
Buy
-5.07%
Downside
Reiterated
07/08/26
RBC Capital Keeps Their Buy Rating on Charles River Labs (CRL)
Barclays Analyst forecast on MX:CRL
Luke Sergott
Barclays
Barclays
$3,846.56
Buy
-2.86%
Downside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL), Incyte (NASDAQ: INCY) and Pfizer (NYSE: PFE)
Bank of America Securities Analyst forecast on MX:CRL
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
06/05/26
Analysts Are Bullish on Top Healthcare Stocks: Charles River Labs (CRL), TransMedics Group (TMDX)
TD Cowen Analyst forecast on MX:CRL
Charles Rhyee
TD Cowen
TD Cowen
$4,108.82
Buy
3.76%
Upside
Reiterated
06/04/26
We reiterate our Buy rating
William Blair Analyst forecast on MX:CRL
Max Smock
William Blair
William Blair
―
Buy
―
Reiterated
06/02/26
Max Smock Reiterates Buy on Charles River Laboratories, Citing Achievable 2026 Targets and Margin Expansion Upside
Jefferies Analyst forecast on MX:CRL
David Windley
Jefferies
Jefferies
$3,933.98
Buy
-0.66%
Downside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (NASDAQ: PSTV) and Charles River Labs (NYSE: CRL)
Robert W. Baird Analyst forecast on MX:CRL
Eric Coldwell
Robert W. Baird
Robert W. Baird
$3,496.87→$3,724.17
Buy
-5.96%
Downside
Reiterated
05/08/26
Charles River price target raised to $213 from $200 at BairdCharles River price target raised to $213 from $200 at Baird
Evercore ISI Analyst forecast on MX:CRL
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$3,496.87→$3,846.56
Buy
-2.86%
Downside
Reiterated
05/08/26
Charles River price target raised to $220 from $200 at Evercore ISICharles River price target raised to $220 from $200 at Evercore ISI
J.P. Morgan Analyst forecast on MX:CRL
Casey Woodring
J.P. Morgan
J.P. Morgan
$2,884.92→$2,797.5
Hold
-29.36%
Downside
Assigned
04/13/26
Charles River price target lowered to $160 from $165 at JPMorganCharles River price target lowered to $160 from $165 at JPMorgan
Argus Research Analyst forecast on MX:CRL
David Toung
Argus Research
Argus Research
$3,496.87
Buy
-11.70%
Downside
Upgraded
11/17/25
Charles River upgraded to Buy from Hold at ArgusCharles River upgraded to Buy from Hold at Argus
Deutsche Bank Analyst forecast on MX:CRL
Justin Bowers
Deutsche Bank
Deutsche Bank
$3,147.18→$3,234.61
Buy
-18.32%
Downside
Reiterated
08/07/25
Deutsche Bank Keeps Their Buy Rating on Charles River Labs (CRL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Charles River Labs

3 Months
David WindleyJefferies
Success Rate
25/43 ratings generated profit
58%
Average Return
+4.43%
reiterated a buy rating 3 months ago
Copying David Windley's trades and holding each position for 3 Months would result in 58.14% of your transactions generating a profit, with an average return of +4.43% per trade.
1 Year
David WindleyJefferies
Success Rate
34/43 ratings generated profit
79%
Average Return
+15.12%
reiterated a buy rating 3 months ago
Copying David Windley's trades and holding each position for 1 Year would result in 79.07% of your transactions generating a profit, with an average return of +15.12% per trade.
2 Years
David WindleyJefferies
Success Rate
34/43 ratings generated profit
79%
Average Return
+21.58%
reiterated a buy rating 3 months ago
Copying David Windley's trades and holding each position for 2 Years would result in 79.07% of your transactions generating a profit, with an average return of +21.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRL Analyst Recommendation Trends

Rating
Feb 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
23
24
21
18
18
Hold
34
35
54
70
65
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
59
75
88
83
In the current month, CRL has received 18 Buy Ratings, 65 Hold Ratings, and 0 Sell Ratings. CRL average Analyst price target in the past 3 months is 4,024.90.
Each month's total comprises the sum of three months' worth of ratings.

CRL Financial Forecast

CRL Earnings Forecast

Next quarter’s earnings estimate for CRL is $47.76 with a range of $46.75 to $50.76. The previous quarter’s EPS was $35.93. CRL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.44% of the time in the same period. In the last calendar year CRL has Performed in-line its overall industry.
Next quarter’s earnings estimate for CRL is $47.76 with a range of $46.75 to $50.76. The previous quarter’s EPS was $35.93. CRL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.44% of the time in the same period. In the last calendar year CRL has Performed in-line its overall industry.

CRL Sales Forecast

Next quarter’s sales forecast for CRL is $17.03B with a range of $16.71B to $17.76B. The previous quarter’s sales results were $17.37B. CRL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 38.92% of the time in the same period. In the last calendar year CRL has Performed in-line its overall industry.
Next quarter’s sales forecast for CRL is $17.03B with a range of $16.71B to $17.76B. The previous quarter’s sales results were $17.37B. CRL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 38.92% of the time in the same period. In the last calendar year CRL has Performed in-line its overall industry.

CRL Stock Forecast FAQ

What is MX:CRL’s average 12-month price target, according to analysts?
Based on analyst ratings, Charles River Laboratories Intl’s 12-month average price target is 4,024.90.
    What is MX:CRL’s upside potential, based on the analysts’ average price target?
    Charles River Laboratories Intl has 1.64% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Charles River Laboratories Intl a Buy, Sell or Hold?
          Charles River Laboratories Intl has a consensus rating of Strong Buy, which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Charles River Laboratories Intl’s share price target?
            The average share price target for Charles River Laboratories Intl is 4,024.90. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $4,633.35 ,and the lowest forecast is $3,724.17. The average share price target represents 1.64% Increase from the current price of $3,960.
              What do analysts say about Charles River Laboratories Intl?
              Charles River Laboratories Intl’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Charles River Laboratories Intl?
                To buy shares of MX:CRL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.